Cargando…

Combination Iron Chelation Therapy with Deferiprone and Deferasirox in Iron-Overloaded Patients with Transfusion-Dependent β-Thalassemia Major

There are few papers on the combination therapy of deferiprone (DFP) and deferasirox (DFX) in iron-overloaded patients with transfusion-dependent β-thalassemia major (β-TM). A total of 6 patients with β-TM (5 males and 1 female) with a mean age of 23.8±5.8 years (ranging from 17 to 31) used this tre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Karami, Hossein, Kosaryan, Mehrnoush, Amree, Arash Hadian, Darvishi-Khezri, Hadi, Mousavi, Masoomeh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	PAGEPress Publications, Pavia, Italy 2017
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5264545/ https://www.ncbi.nlm.nih.gov/pubmed/28243431 http://dx.doi.org/10.4081/cp.2017.912

Ejemplares similares

Potential Effects of Silymarin and Its Flavonolignan Components in Patients with β-Thalassemia Major: A Comprehensive Review in 2015
por: Darvishi Khezri, Hadi, et al.
Publicado: (2016)

Efficacy and safety of combined oral iron chelation therapy with deferasirox and deferiprone in a patient with beta-thalassemia major and persistent iron overload
por: Alavi, Samin, et al.
Publicado: (2014)

Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes
por: Kontoghiorghe, Christina N, et al.
Publicado: (2016)

Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with nontransfusion-dependent thalassemia syndromes
por: Taher, Ali T, et al.
Publicado: (2016)

Ebselen: A promising therapy protecting cardiomyocytes from excess iron in iron-overloaded thalassemia patients
por: Ghazaiean, Mobin, et al.
Publicado: (2023)

Comparison of iron chelation effects of deferoxamine, deferasirox, and combination of deferoxamine and deferiprone on liver and cardiac T2* MRI in thalassemia maior
por: Ansari, Shahla, et al.
Publicado: (2017)

Iron Chelation Therapy with Deferasirox in the Management of Iron Overload in Primary Myelofibrosis
por: Elli, Elena Maria, et al.
Publicado: (2014)

MRI prospective survey on cardiac and hepatic iron in transfusion-dependent thalassemia intermedia patients treated with desferrioxamine, deferiprone and deferasirox
por: Meloni, Antonella, et al.
Publicado: (2015)

Iron Overload and Chelation Therapy in Non-Transfusion Dependent Thalassemia
por: Bou-Fakhredin, Rayan, et al.
Publicado: (2017)

Efficacy and Safety of Combined Deferiprone and Deferasirox in Iron-Overloaded Patients: A Systematic Review
por: Salem, Ahmed, et al.
Publicado: (2023)

Treatment Status of Patients with B-Thalassemia Major in Northern Iran: Thalassemia Registry System
por: KOSARYAN, Mehrnoush, et al.
Publicado: (2019)

Treating thalassemia major-related iron overload: the role of deferiprone
por: Berdoukas, Vasilios, et al.
Publicado: (2012)

Single-center retrospective study of the effectiveness and toxicity of the oral iron chelating drugs deferiprone and deferasirox
por: Olivieri, Nancy F., et al.
Publicado: (2019)

Silymarin therapy and improvement of cardiac outcome in patients with β-thalassemia major
por: Khezri, Hadi Darvishi, et al.
Publicado: (2016)

The improvement of pulmonary artery pressure after bosentan therapy in patients with β-thalassemia and Doppler-defined pulmonary arterial hypertension
por: Karami, Hossein, et al.
Publicado: (2018)

P1511: EFFICACY AND SAFETY OF COMBINATION IRON CHELATION THERAPY WITH DEFERIPRONE AND DEFERASIROX IN PATIENTS WITH Β-THALASSEMIA MAJOR: A SYSTEMATIC LITERATURE REVIEW
por: Piga, A., et al.
Publicado: (2022)

Correction: Single-center retrospective study of the effectiveness and toxicity of the oral iron chelating drugs deferiprone and deferasirox
Publicado: (2019)

Chelation Therapy with Oral Solution of Deferiprone in Transfusional Iron-Overloaded Children with Hemoglobinopathies
por: Makis, Alexandros, et al.
Publicado: (2013)

Approaching low liver iron burden in chelated patients with non-transfusion-dependent thalassemia: the safety profile of deferasirox
por: Taher, Ali T, et al.
Publicado: (2014)

Iron chelation monotherapy in transfusion-dependent beta-thalassemia major patients: a comparative study of deferasirox and deferoxamine
por: Hassan, Mohamed Abdel Malik, et al.
Publicado: (2016)

Amlodipine: Can act as an antioxidant in patients with transfusion‐dependent β‐thalassemia? A double‐blind, controlled, crossover trial
por: Darvishi‐Khezri, Hadi, et al.
Publicado: (2022)

Comparison of deferasirox and deferoxamine effects on iron overload and immunological changes in patients with blood transfusion-dependent β-thalassemia
por: Al-Kuraishy, Hayder M., et al.
Publicado: (2017)

Safety and Efficacy of the New Combination Iron Chelation Regimens in Patients with Transfusion-Dependent Thalassemia and Severe Iron Overload
por: Origa, Raffaella, et al.
Publicado: (2022)

Chelation of Thallium (III) in Rats Using Combined Deferasirox and Deferiprone Therapy
por: Salehi, Samie, et al.
Publicado: (2017)

Moderate to severe liver siderosis and raised AST are independent risk factors for vitamin D insufficiency in β-thalassemia patients
por: Darvishi-Khezri, Hadi, et al.
Publicado: (2020)

Ferritin thresholds for cardiac and liver hemosiderosis in β-thalassemia patients: a diagnostic accuracy study
por: Darvishi-Khezri, Hadi, et al.
Publicado: (2022)

Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with β-thalassaemia: the ESCALATOR study
por: Taher, Ali, et al.
Publicado: (2009)

Therapeutic Value of Combined Therapy with Deferasirox and Silymarin on Iron Overload in Children with Beta Thalassemia
por: Hagag, Adel A., et al.
Publicado: (2013)

Effect of deferiprone or deferoxamine on right ventricular function in thalassemia major patients with myocardial iron overload
por: Smith, Gillian C, et al.
Publicado: (2011)

A T2* MRI prospective survey on heart iron in thalassemia major patients treated with sequential deferipron-desferrioxamine versus deferasirox
por: Pepe, Alessia, et al.
Publicado: (2011)

A T2* MRI prospective survey on heart iron in thalassemia major patients treated with deferasirox versus deferiprone and desferrioxamine in monotherapy
por: Pepe, Alessia, et al.
Publicado: (2011)

Korean Guideline for Iron Chelation Therapy in Transfusion-Induced Iron Overload
por: Jang, Jun Ho, et al.
Publicado: (2013)

Pharmacogenetic Study of Deferasirox, an Iron Chelating Agent
por: Lee, Ji Won, et al.
Publicado: (2013)

Effect of Iron-Chelator Deferiprone on the In Vitro Growth of Staphylococci
por: Kim, Choon-Mee, et al.
Publicado: (2009)

Combination therapy with a Tmprss6 RNAi-therapeutic and the oral iron chelator deferiprone additively diminishes secondary iron overload in a mouse model of β-thalassemia intermedia
por: Schmidt, Paul J, et al.
Publicado: (2015)

Administration of Intravenous Zoledronic Acid Every 3 Months vs. Annually in β-thalassemia Patients with Low Bone Mineral Density: a Retrospective Comparison of Efficacy
por: Darvishi-Khezri, Hadi, et al.
Publicado: (2018)

Iron Chelation Therapy with Deferasirox Results in Improvement of Liver Enzyme Level in Patients with Iron Overload-Associated Liver Dysfunction
por: Miura, Yasuo, et al.
Publicado: (2010)

Update on the use of deferasirox in the management of iron overload
por: Taher, Ali, et al.
Publicado: (2009)

Exjade® (deferasirox, ICL670) in the treatment of chronic iron overload associated with blood transfusion
por: Cappellini, Maria Domenica
Publicado: (2007)

Estimates of the effect on hepatic iron of oral deferiprone compared with subcutaneous desferrioxamine for treatment of iron overload in thalassemia major: a systematic review
por: Caro, J Jaime, et al.
Publicado: (2002)

Cannot write session to /tmp/vufind_sessions/sess_00acb4pv3j5iksc910c14jpjde